Terminal › Stocks › ACXP

Acurx Pharmaceuticals, Inc. (ACXP) Stock

Healthcare · Biotechnology · US

$2.42 -21.94%

Last updated Jun 18, 2026 23:54 UTC

ACXP Key Statistics

Market Cap$3.84M

P/E (TTM)-0.41

P/S (TTM)—

P/B (TTM)0.69

Revenue (TTM)$0.00

EPS (TTM)$-5.93

Dividend Yield—

ROE (TTM)-215.55%

Net Margin0.00%

Gross Margin0.00%

52W High$7.54

52W Low$1.33

Analyst ViewBuy

Price Target—

Employees4

Volume201,590

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

CEO: David Luci. Company website

See ACXP live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open ACXP in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.